Lista de obras - Alessandra Gennari - Dominio Público Uruguay

18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT

artículo científico publicado en 2015

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2017

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2017

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2016

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer ⬇️

artículo científico publicado el 25 de junio de 2012

A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.

artículo científico publicado en 2017

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

artículo científico publicado en 2004

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab

artículo científico publicado en 2014

Anthracycline-free therapy for HER2-amplified breast cancer.

artículo científico publicado en 2013

Anthracyclines-paclitaxel combinations in the treatment of breast cancer.

artículo científico publicado en 1997

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

artículo científico publicado en 2016

Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy

scientific article published on 14 August 2013

Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.

artículo científico publicado en 2015

Cancer and fertility preservation: international recommendations from an expert meeting

artículo científico publicado en 2016

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

artículo científico publicado en 1999

Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review ⬇️

artículo científico publicado el 1 de noviembre de 2011

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

artículo científico publicado en 2017

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

artículo científico publicado en 1997

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.

artículo científico publicado en 2016

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

artículo científico publicado en 2011

Editorial: Why are guidelines not followed in clinical practice?

artículo científico publicado en 2016

Exemestane for breast cancer prevention: a critical shift?

artículo científico publicado en 2012

Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.

artículo científico publicado en 2011

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study* ⬇️

artículo científico publicado el 1 de julio de 2001

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

artículo científico publicado en 2007

Identification and validation of a new set of five genes for prediction of risk in early breast cancer

artículo científico publicado en 2013

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

artículo científico publicado en 2016

Insulin breast cancer connection: confirmatory data set the stage for better care

artículo científico publicado en 2010

Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial

artículo científico publicado en 2020

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

artículo científico publicado en 2015

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

artículo científico publicado en 2006

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

artículo científico publicado en 2010

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

artículo científico publicado en 2018

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

scientific article published on December 2008

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study

artículo científico publicado en 1996

Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

artículo científico publicado en 2002

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

artículo científico publicado en 2002

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

scientific article published on 27 December 2018

Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel

artículo científico publicado en 1996

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

artículo científico publicado en 2005

The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it.

artículo científico

Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.

artículo científico publicado en 2002

Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.

artículo científico publicado en 2012

Lista de obras de Alessandra Gennari

18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer ⬇️

A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab

Anthracycline-free therapy for HER2-amplified breast cancer.

Anthracyclines-paclitaxel combinations in the treatment of breast cancer.

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy

Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.

Cancer and fertility preservation: international recommendations from an expert meeting

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review ⬇️

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

Editorial: Why are guidelines not followed in clinical practice?

Exemestane for breast cancer prevention: a critical shift?

Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study* ⬇️

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

Identification and validation of a new set of five genes for prediction of risk in early breast cancer

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

Insulin breast cancer connection: confirmatory data set the stage for better care

Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study

Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it.

Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.

Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.